UP!

CHRS $18.71   View long term graphs

Coherus BioSciences Inc.
Industry Biopharmaceutical
Founded 2010
Headquarters Redwood City, California, United States
Key people
Dennis M. Lanfear (President, CEO & Chairman)
Website www.coherus.com

Coherus BioSciences is an American biopharmaceutical company focused on developing and commercializing biosimilar drugs.

Coherus BioSciences was founded in 2010 as a pure-play biosimilar company with headquarters in Redwood City, California. The company is publicly traded on the NASDAQ Stock Market with the tag NASDAQ:CHRS.

Coherus develops a type of biologic products called biosimilars.

2016 - Deloitte’s Technology Fast 500 award

News

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-25 Future report Set alerts
Q3 2020 2020-11-04 Future report Set alerts
Q2 2020 2020-08-06 0.70 0.70
Q1 2020 2020-05-07 0.48 0.48
Q4 2019 2020-02-27 0.56 0.51
Q3 2019 2019-11-06 0.63 0.63
Q2 2019 2019-08-01 0.32 0.32
Q1 2019 2019-05-09 -0.29 -0.29
Q4 2018 2019-02-28 -0.92 -0.92
Q3 2018 2018-11-08 -0.87 -0.87

Ratings

2016-03-01 Lower Price Target JPMorgan Chase & Co. Overweight $37.00 to $35.00
2016-01-19 Initiated Coverage Credit Suisse Outperform $25.00
2016-01-19 Initiated Coverage Credit Suisse Group AG Outperform $25.00
2015-11-23 Initiated Coverage Barclays Overweight $46.00
2015-11-23 Initiated Coverage Barclays PLC Overweight $46.00
2015-02-17 Boost Price Target JPMorgan Chase & Co. Overweight $20.00 to $35.00
2014-12-02 Initiated Coverage Credit Suisse Outperform $22.00
2014-12-02 Initiated Coverage JPMorgan Chase & Co. Overweight
2014-12-01 Initiated Coverage Cowen and Company Outperform $45.00
2016-03-01 Lower Price Target JPMorgan Chase & Co. Overweight $37.00 to $35.00
2016-01-19 Initiated Coverage Credit Suisse Outperform $25.00
2016-01-19 Initiated Coverage Credit Suisse Group AG Outperform $25.00
2015-11-23 Initiated Coverage Barclays Overweight $46.00
2015-11-23 Initiated Coverage Barclays PLC Overweight $46.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks

Comments